Patients must have either measurable or evaluable limited-stage DLBCL          * Patients rendered free of measurable or evaluable disease by virtue of biopsy (resection) are also eligible; NOTE: if patient has measurable disease it must be documented on the Lymphoma Baseline Tumor Assessment Form* All measurable disease must be assessed within 28 days prior to registration* Patients with non-measurable disease with or without measurable disease must have all non-measurable disease assessed within 42 days prior to registration
Patients must have measurable disease (Phase I)
Patients must have measurable disease; must have at least one non-nodal lesion
Measurable disease by RECIST criteria* For the lead-in, non-randomized portion of Part I, either measurable or evaluable disease is acceptable* For Part I, randomized portion, measurable disease is required
Measurable or non-measurable (evaluable) tumor parameter(s); non-measurable tumor parameters will be defined as not having bi-dimensional measurements (i.e., gastric or marrow involvement) but can be followed for response by other diagnostic tests such as gallium, PET imaging and/or bone marrow biopsy
Patients must have at least one 1.5 cm bidimensional measurable lesion
All patients must have measurable residual disease defined as tumor measurable in two perpendicular diameters on magnetic resonance imaging (MRI); measurements are required for both the solid and cystic components
Patient must have measurable disease or non-measurable disease, defined as one or more of the following holding true:* Measurable disease:** Serum M-protein >= 1.0 g/dL (>= 0.5 g/dL for IgA or IgM myeloma) and/or** Urine M-protein >= 200 mg/24 hours and/or** Involved serum free light chain level >= 10 mg/dL AND an abnormal serum free light chain ratio* For non-measurable disease:** Baseline marrow burden of myeloma of at least 30%
RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Patient must have measurable disease or non-measurable disease after progression on pomalidomide + dexamethasone, defined as one or more of the following holding true:* Measurable disease:** Serum M-protein >= 0.5 g/dL and/or** Urine M-protein >= 200 mg/24 hours and/or** Involved serum free light chain level >= 10 mg/dL AND an abnormal serum free light chain ratio* For non-measurable disease:** Marrow burden of myeloma of at least 30%
Part D: Patients must have measurable disease for Part D
Patients must have measurable disease
Measurable disease
Patients must have measurable disease; all sites of disease must be evaluated within 4 weeks prior to randomization
Patients must have measurable disease based on RECIST 1.1
Patients must have measurable disease per RECIST 1.1 criteria; all sites of disease must be evaluated within 4 weeks prior to randomization
Patients must have measurable disease
All subjects must have measurable disease in 2-dimensions on MRI scan of the brain; disease should be consistently measured with the two largest perpendicular dimensions
INCLUSION CRITERIA FOR STRATUM C: All subjects must have measurable disease in 2-dimensions on MRI scan of the brain and/or spine; disease should be consistently measured with the two largest perpendicular dimensions
Measurable disease
Re-registration: measurable disease
Documentation of disease:* Histologic documentation: histologically proven intracranial meningioma as documented by central pathology review* Molecular documentation: presence of SMO, PTCH1 or NF2 mutation in tumor sample as documented by central laboratory* Progressive OR residual disease, as defined by the following: ** Residual measurable disease: residual measurable disease immediately after surgery without requirement for progression; for grade I disease, progression pre-operatively needs to be documented, with an increase in size of the measurable primary lesion on imaging by 25% or more (bidirectional area); the change must occur between scans separated by no more than 12 months; residual measurable disease will be defined by bidimensionally measurable lesions with clearly defined margins by MRI scans, with a minimum diameter of 10 mm in both dimensions** Progressive measurable disease: progression defined as an increase in size of the measurable primary lesion on imaging by 25% or more (bidirectional area); the change must occur between scans separated by no more than 12 months** Post radiation patients: patients with measurable and progressive meningioma who have received radiation are potentially eligible, but need to show evidence of progressive disease after completion of radiation; at least 24 weeks must have elapsed from completion of radiation to registration
Measurable disease: measurable disease is defined by a bidimensionally measurable main lesion on MRI or computed tomography (CT) images (MRI preferred) with clearly defined margins; multifocal disease is allowed
Measurable disease by RECIST 1.1
Measurable disease
Measurable disease
COHORT A: Patients must have histologically or cytologically confirmed primary desmoplastic melanoma that is deemed resectable; the decision to perform surgery on patients must be based on good clinical judgment; eligible patients for surgical resection must have disease that, in the judgment of the surgeon, is deemed completely resectable resulting in free surgical margins; patients must have residual disease after initial biopsy which can be measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; residual disease can either be confirmed with fine-needle aspiration (FNA) or if measurable disease is present, no FNA needs to be obtained OR
Patients must have measurable disease as per RECIST (version 1.1)
There must be measurable disease at study entry* Note: a measurable node must have an LDi (longest diameter) greater than 1.5 cm; a measurable extranodal lesion should have an LDi greater than 1.0 cm; all tumor measurements must be recorded in millimeters (or decimal fractions of centimeters)
Must not have received any prior radiation to any sites of measurable disease
Patients must have radiographically measurable disease; measurable disease is defined as the presence of at least one lesion on magnetic resonance imaging (MRI) or computed tomography (CT) scan that can be accurately measured with the longest diameter a minimum of 10 mm in at least one dimension (CT scan slice thickness no greater than 5 mm)* Note: The following do NOT qualify as measurable disease: ** Malignant fluid collections (e.g., ascites, pleural effusions)** Bone marrow infiltration** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) ** Elevated tumor markers in plasma or cerebrospinal fluid (CSF)** Previously radiated lesions that have not demonstrated clear progression post radiation ** Leptomeningeal lesions that do not meet the measurement parameters noted above
Patients must have measurable disease by RECIST v1.1, or evaluable disease with bone metastases demonstrated by Tc99 bone scan; patients with bone metastases only are allowed (NOTE: nodes >= 1.5 cm (not >= 2 cm) in the short axis are considered measurable, per The Prostate Cancer Working Group 3 [PCWG3])
Patients must have measurable disease
For the expansion cohort only: measurable disease by RECIST v1.1 with at least one measurable target lesion
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have iobenguane (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice* Note: The following do not qualify as measurable disease: ** Malignant fluid collections (e.g., ascites, pleural effusions)** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma** Elevated tumor markers in plasma or cerebrospinal fluid (CSF) ** Previously radiated lesions that have not demonstrated clear progression post radiation ** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease outside of biopsy site present per immune related (ir)RECIST criteria
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have iobenguane (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice* Note: The following do not qualify as measurable disease: ** Malignant fluid collections (e.g., ascites, pleural effusions)** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma** Elevated tumor markers in plasma or cerebrospinal fluid (CSF) ** Previously radiated lesions that have not demonstrated clear progression post radiation ** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have metaiodobenzylguanidine (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice; Note: The following do not qualify as measurable disease: * Malignant fluid collections (e.g., ascites, pleural effusions)* Bone marrow infiltration except that detected by MIBG scan for neuroblastoma* Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma* Elevated tumor markers in plasma or cerebrospinal fluid (CSF)* Previously radiated lesions that have not demonstrated clear progression post radiation* Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have MIBG+ evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice; Note: The following do not qualify as measurable disease:* Malignant fluid collections (e.g., ascites, pleural effusions)* Bone marrow infiltration except that detected by MIBG scan for neuroblastoma* Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma* Elevated tumor markers in plasma or cerebrospinal fluid (CSF)* Previously radiated lesions that have not demonstrated clear progression post radiation* Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have metaiodobenzylguanidine (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice* Note: The following do not qualify as measurable disease: ** Malignant fluid collections (e.g., ascites, pleural effusions)** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma** Elevated tumor markers in plasma or cerebrospinal fluid (CSF) ** Previously radiated lesions that have not demonstrated clear progression post radiation ** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1** Bone lesions without an associated soft tissue mass >= 10 mm in greatest diameter; bone lesions with an associated soft tissue mass >= 10 mm in greatest diameter imaged by computed tomography (CT) or MRI are considered measurable
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have iobenguane (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice* Note: the following do not qualify as measurable disease: ** Malignant fluid collections (e.g., ascites, pleural effusions)** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma** Elevated tumor markers in plasma or cerebrospinal fluid (CSF) ** Previously radiated lesions that have not demonstrated clear progression post radiation ** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: At the time of treatment with subprotocol specified therapy, the patients must have radiographically measurable disease; patients with neuroblastoma who do not have measurable disease but have iobenguane (MIBG) positive (+) evaluable are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice* Note: The following do not qualify as measurable disease:** Malignant fluid collections (e.g., ascites, pleural effusions)** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma** Elevated tumor markers in plasma or CSF ** Previously radiated lesions that have not demonstrated clear progression post radiation ** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
